"A Big Unknown in Covid-19 Vaccine Development: How Long Will Protection Last?" - Jared S. Hopkins

CastleVax Inc. Receives BARDA Project NextGen Award Valued at up to $338 Million to Advance Intranasal NDV-based COVID-19 Booster Vaccine into Phase 2b Clinical Efficacy Testing

People with Long COVID Have Distinct Hormonal and Immune Differences From Those Without This Condition

UCSF QBI, University College London, and Mount Sinai Identify Shared Molecular Mechanisms Across SARS-CoV-2 Variants that Allow Virus to Thrive Despite Vaccination

Mount Sinai Receives $6.2 Million Grant from the Steven & Alexandra Cohen Foundation for the Clinical Care of Long Lyme Disease

Mount Sinai Awarded $3.4 Million to Study Prostate Cancer in People With HIV

Mount Sinai Receives NIH Grant to Develop Vaccines That Can Protect Against Many Different Types of Coronaviruses

Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine: Implications for Infection Prevention and Transmission

High-Dose Anticoagulation Can Reduce Intubations and Improve Survival for Hospitalized COVID-19 Patients

First Stem Cells From a Bat Species Known to Harbor SARS-CoV-2 Could Shed Light on Virus Survival and Molecular Adaptability

COVID-19 Vaccination Linked to Fewer Cardiac Events

Mount Sinai Study Links Molecular Changes to Long COVID a Year After Hospitalization